MaaT Pharma SA
EPA:MAAT.PA
7.6 (EUR) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.861 | 0.861 | 0.425 | 0.425 | 1.378 | 0.689 | 0.936 | 0.468 | 0.494 | 0.247 | 0.587 | 0.294 | 0.385 | 0.193 | -0.568 | -0.568 | 0.568 | 0.568 |
| Cost of Revenue
| 0.269 | 0.269 | 0.297 | 0.297 | 0.484 | 0.142 | 0.489 | 0.285 | 0.258 | 0.036 | 0.349 | 0.152 | 0.014 | 0.014 | 0.105 | 0.016 | 0.059 | 0 |
| Gross Profit
| 0.592 | 0.592 | 0.128 | 0.128 | 0.894 | 0.547 | 0.447 | 0.183 | 0.236 | 0.211 | 0.238 | 0.142 | 0.372 | 0.179 | -0.673 | -0.584 | 0.509 | 0.568 |
| Gross Profit Ratio
| 0.688 | 0.688 | 0.301 | 0.301 | 0.649 | 0.794 | 0.478 | 0.391 | 0.478 | 0.854 | 0.405 | 0.484 | 0.965 | 0.93 | 1.185 | 1.027 | 0.896 | 1 |
| Reseach & Development Expenses
| 6.348 | 6.348 | 5.601 | 5.601 | 9.65 | 4.825 | 6.844 | 3.492 | 7.328 | 3.664 | 4.662 | 2.381 | 4.27 | 2.192 | 3.277 | 1.688 | 2.669 | 1.362 |
| General & Administrative Expenses
| 1.436 | 1.436 | 1.278 | 1.278 | 1.089 | 1.089 | 0.903 | 0.903 | 1.058 | 1.058 | 0.752 | 0.752 | 0.529 | 0.529 | 0.584 | 0.584 | 0 | 0 |
| Selling & Marketing Expenses
| 0.154 | 0.154 | 0.055 | 0.055 | 0.271 | 0.271 | 0.183 | 0.183 | 0.07 | 0.07 | 0.135 | 0.135 | 0.044 | 0.044 | 0.05 | 0.05 | 0 | 0 |
| SG&A
| 1.59 | 1.59 | 1.333 | 1.333 | 2.518 | 1.359 | 2.12 | 1.086 | 2.069 | 1.128 | 1.688 | 0.887 | 1.141 | 0.573 | 0.733 | 0.359 | 0.545 | 0.275 |
| Other Expenses
| -0.968 | -0.968 | -1.101 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 6.97 | 6.97 | 5.833 | 5.834 | 12.168 | 4.818 | 8.964 | 3.281 | 9.397 | 3.9 | 6.35 | 2.599 | 5.411 | 2.171 | 4.01 | 0.975 | 3.214 | 1.637 |
| Operating Income
| -6.378 | -6.378 | -5.705 | -5.704 | -11.274 | -4.268 | -8.517 | -3.094 | -9.161 | -3.684 | -6.112 | -2.456 | -5.171 | -1.991 | -4.115 | -1.558 | -3.273 | -1.069 |
| Operating Income Ratio
| -7.412 | -7.412 | -13.422 | -13.421 | -8.181 | -6.194 | -9.099 | -6.611 | -18.545 | -14.915 | -10.412 | -8.366 | -13.431 | -10.343 | 7.245 | 2.742 | -5.762 | -1.881 |
| Total Other Income Expenses Net
| -0.05 | -0.05 | 0.064 | 0.063 | 0.739 | 0.05 | 0.472 | -0.054 | 0.302 | -0.025 | 0.2 | -0.031 | 0.108 | -0.032 | 0.218 | -0.009 | 0.378 | -0.016 |
| Income Before Tax
| -6.428 | -6.428 | -5.641 | -5.641 | -10.535 | -4.218 | -8.045 | -3.148 | -8.859 | -3.709 | -5.912 | -2.486 | -5.063 | -2.023 | -3.897 | -1.567 | -2.895 | -1.084 |
| Income Before Tax Ratio
| -7.47 | -7.47 | -13.273 | -13.273 | -7.645 | -6.121 | -8.595 | -6.726 | -17.933 | -15.014 | -10.072 | -8.47 | -13.151 | -10.512 | 6.861 | 2.758 | -5.097 | -1.908 |
| Income Tax Expense
| -1.62 | 0 | -1.533 | 0 | -2.1 | 0 | -1.749 | 0 | -1.442 | 0 | -0.94 | 0 | -1.016 | 0 | -0.764 | 0 | -0.727 | 0 |
| Net Income
| -6.428 | -6.428 | -5.641 | -5.641 | -8.435 | -4.218 | -6.296 | -3.148 | -7.417 | -3.709 | -4.972 | -2.486 | -4.047 | -2.023 | -3.133 | -1.567 | -2.168 | -1.084 |
| Net Income Ratio
| -7.47 | -7.47 | -13.273 | -13.273 | -6.121 | -6.121 | -6.726 | -6.726 | -15.014 | -15.014 | -8.47 | -8.47 | -10.512 | -10.512 | 5.516 | 2.758 | -3.817 | -1.908 |
| EPS
| -0.53 | -0.53 | -0.49 | -0.49 | -0.76 | -0.38 | -0.64 | -0.32 | -0.75 | -0.38 | -0.5 | -0.65 | -19.6 | -1.96 | -15.18 | -1.52 | -10.5 | -1.05 |
| EPS Diluted
| -0.53 | -0.53 | -0.49 | -0.49 | -0.76 | -0.38 | -0.64 | -0.32 | -0.75 | -0.38 | -0.5 | -0.65 | -19.6 | -1.96 | -15.18 | -1.52 | -10.5 | -1.05 |
| EBITDA
| -6.32 | -6.32 | -5.652 | -5.652 | -10.177 | -4.218 | -7.65 | -3.02 | -8.624 | -3.638 | -5.667 | -2.406 | -4.854 | -1.951 | -3.778 | -1.531 | -2.805 | -1.043 |
| EBITDA Ratio
| -7.344 | -7.344 | -13.299 | -13.299 | -8.036 | -6.122 | -8.84 | -6.452 | -18.168 | -14.729 | -10.101 | -8.196 | -13.055 | -10.132 | 7.06 | 2.695 | -5.658 | -1.836 |